CD274 and non-small cell lung carcinoma: N-803 has been shown to boost antitumor response of anti-PD-L1 antibody in triple negative breast and colon cancers in vivo and its combination with anti-PD-1 monoclonal antibody, Nivolumab, has been verified in safety to treat refractory metastatic non-small cell lung cancer patients with observed tumor responses [17].